Get all your news in one place.

100’s of premium titles.
One app.

Start reading

Get all your news in one place.

100’s of premium titles. One news app.

Start reading

The Latest Breaking News on Pharma

Lincoln Park life sciences hub adds 4 biotech research firms

The new tenants will bring the building at 2430 N. Halsted St. to 80% occupancy.

Chicago Sun-Times

Analyzing Pharma Stock Giants: JNJ, MRK, and ABBV

The pharmaceutical industry is set for long-term growth due to growing demand for quality drugs and therapies, an aging population, and the rise in lifestyle-related diseases. Now, let's explore the investment potential of industry giants Merck & Co (MRK), Johnson & Johnson (JNJ), and AbbVie (ABBV). Keep reading.

StockNews.com

Vertex Pharmaceuticals (VRTX) Post-Earnings Analysis: Is It Time to Buy the Stock?

After a solid third-quarter earnings report, does Vertex Pharmaceuticals (VRTX) deserve a place in your portfolio? Let’s look at its financial metrics to gauge its prospects….

StockNews.com

From analysis to the latest developments in health,
read the most diverse news in one place.

Becton Dickinson & Co. (BDX) Earnings Moves: A Buy or Sell for Investors?

Becton Dickinson & Co. (BDX) is expected to report steady growth for its fiscal fourth quarter ended September 2023, scheduled to be released on November 9. While the stock is witnessing weakness over the past month, will the quarterly report be able to spur a rally? Read on.

StockNews.com

Biogen (BIIB) Earnings Spotlight: Is the Biotech Stock a Buy or Sell?

Biotech major Biogen (BIIB) will report its third-quarter results on November 8. Its EPS and revenue are expected to decline year-over-year. However, the FDA approvals for new drugs received by the company this year will likely support its long-term growth. Let’s discuss the potential road ahead for the stock….

StockNews.com

Gilead Sciences (GILD) Earnings Forecast and Gameplan

Gilead Sciences (GILD) boasts an impressive product portfolio and has surpassed the consensus estimate on the topline in each of the trailing four quarters. With the company gearing up to post its third quarter results, is GILD a wise investment now? Read on.

StockNews.com

Michelle Mone admits involvement with 'VIP lane' PPE firm for the first time

TORY peer Michelle Mone has admitted her involvement with a “VIP lane” PPE company for the first time.

The National (Scotland)

Read news from The Economist, FT, and more,
with one subscription

3 Pharma Stocks Providing Consistent Gains for Investors

The pharmaceutical industry is anticipated to be bolstered due to the increasing demand for chronic disease management and the rising requirements of an aging demographic. Given the industry’s solid prospects, investors could buy quality pharma stocks Eton Pharmaceuticals (ETON), Ipsen S.A. (IPSEY), and Merck & Co. (MRK) for consistent gains.…

StockNews.com

3 Pharma Stocks to Capitalize on With Potential Upside

The pharma industry’s prospects look bright, thanks to rising demand for innovative drugs. Thus, pharma stocks with potential upside, like GSK plc (GSK), Johnson & Johnson (JNJ), and Bristol-Myers Squibb Company (BMY), could be wise investments to capitalize on right now. Read on….

StockNews.com

Minister vows to be ‘robust’ in fighting for drugs policy funding

Elena Whitham rejected claims there has been a real-terms cut in investment.

The Independent UK

3 Top-Rated Pharma Stocks Worth Including in Your November Portfolio

The pharmaceutical sector is booming with increasing global healthcare demands and technological progress. Hence, top-rated pharma stocks Dr. Reddy’s (RDY), Novo Nordisk (NVO), and AbbVie (ABBV) might be solid additions to one’s portfolio in November. Read more.

StockNews.com

Regeneron Pharmaceuticals (REGN) Earnings Analysis -- Should Investors Brace for Impact?

Regeneron Pharmaceuticals (REGN) has an impressive revenue and earnings surprise history. So, as the company gears up to post its third-quarter report, is REGN the right pick? Read on.

StockNews.com

Eli Lilly & Co. (LLY) Earnings Forecast

Drugmaker Eli Lilly and Company (LLY) is scheduled to release its third-quarter results soon. While its revenue is expected to rise sharply over the prior-year quarter, its earnings are expected to decline. So, how should investors position themselves before the results are out? Read on to learn more….

StockNews.com

These 27 eye products could lead to infections and vision loss, FDA warns

If you find one of the products in your home you need to dispose of it immediately, the FDA says

The Independent UK

Get all your
news in one place.

100’s of premium titles.
One news app.

The Independent UK

Pharmacists prescribe another round of US protests to highlight working conditions

Drugstore employees around the country have started calling in sick to highlight a lack of support from their employers

The Guardian - US

White House urges all US schools to stock overdose reversal drug naloxone

Letter from education department presses for schools to train students and faculty in how to administer medication

The Guardian - UK

New Unilever boss is still getting it wrong on Russia

The Dove and Magnum maker says it wants to make a ‘positive impact’ but pays taxes to a state waging an illegal war in Ukraine

StockNews.com

Amgen (AMGN) Earnings Watch: Buy or Sell?

Amgen (AMGN) is scheduled to report its third-quarter earnings soon, with Wall Street analysts expecting year-over-year improvements in revenue. However, its earnings are expected to miss the consensus estimate. Moreover, the company completed the acquisition of Horizon Therapeutics earlier this month. Considering these factors, is the stock a buy or…

Get all your
news in one place.

100’s of premium titles.
One news app.

The National (Scotland)

Life-saving overdose reversal drug expanded across Scotland

Community pharmacies across Scotland are being provided with a drug which can reverse overdoses.

The Independent UK

COVID-19 treatments to enter the market with a hefty price tag

The COVID-19 treatments millions of have taken for free from the federal government will enter the private market next week with a hefty price tag

The Independent UK

US government says it plans to go after legal goods tied to illegal fentanyl trade in new strategy

The U.S. Customs and Border Protection has announced a new government-wide strategy that will target not only fentanyl but precursor materials used to make the synthetic opioid

StockNews.com

3 Pharma Stocks With Market Impact to Consider Buying

The pharmaceutical sector is expected to thrive due to the rising demand for advanced medicines to treat lifestyle diseases and its increasing ability to meet quality treatment needs thanks to technological advancements. Therefore, it could be wise to add fundamentally strong pharma stocks Amneal Pharmaceuticals (AMRX), Dr. Reddy’s Laboratories (RDY),…

StockNews.com

3 Pharma Stocks on the Rise - Buy Now

The pharmaceutical industry is well-positioned for long-term growth thanks to rising investments in drug development and technological advancements. Thus, it would be prudent to buy pharma stocks, Sanofi (SNY), Johnson & Johnson (JNJ) and AstraZeneca PLC (AZN). Read on.

Chicago Sun-Times

Amgen cuts Horizon Therapeutics jobs at Deerfield office after acquisition

350 people will be laid off, many of them at Horizon’s U.S. base in Deerfield.

StockNews.com

3 Healthcare Stocks With Strong Stability

The healthcare industry is well-positioned for expansion due to rising healthcare expenditures and growing demand for quality treatment. Given the industry’s solid long-term prospects, investors might consider buying quality stocks Cigna (CI), UnitedHealth Group (UNH) and Elevance Health (ELV). Read on….

1 … 34 35 36 37

People

Kritika SarmahHer

727 stories

Dipanjan BanchurSince

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

the Scottish Government

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.